Skip to main content

Regulation of Cholesterol Biosynthesis and Absorption: Ultimate Management of Dyslipidemia with Statin and Ezetimibe

Buy Article:

$63.00 plus tax (Refund Policy)

Abstract:

Coronary heart disease (CHD) has been one of the leading causes of death in United States, Japan and EU countries. A large bodies of clinical evidence suggests a causative role for elevated cholesterol in atherosclerosis, and supports treatment of hyperlipidemia [1-3]. Nonetheless, fewer than 50% of Americans who are eligible for cholesterol lowering therapy do actually receive it [4, 5]. Moreover, only about one-third of those treated with hyperlipidemia achieve their target LDL-C goal [5]. Tremendous efforts have been taken to the management of hyperlipidemia. The National Cholesterol Education Program (NCEP) Expert Panel in US [6-8] or Japan Atherosclerosis society in Japan [9, 10] has historically provided consensus recommendations on the evaluation and treatment of hyperlipidemia. The trend of recent recommendations continues toward a more aggressive management of patients with elevated cholesterol levels, particularly if they fall in the high-risk category. The purpose of this article is to provide an overview of current concept of controling dyslipidemia especially with new category of cholesterol absorption inhibitor, ezetimibe in addition to HMG CoA reductase inhibitor or statin.





Keywords: Statin; cholesterol absorption; cholesterol synthesis; dyslipidemia; ezetimibe

Document Type: Research Article

DOI: https://doi.org/10.2174/187152208784587854

Publication date: 2008-06-01

More about this publication?
  • Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry aims to cover all the latest and outstanding developments in the medicinal chemistry and rational drug design for the discovery of new Immunology, Endocrine & Metabolic Agents. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in Immunology, Endocrine & Metabolic medicinal chemistry.

    Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments in Immunology, Endocrine & Metabolic drug discovery.
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more